Table 2 Clinicopathological features of development and validation cohorts
Features | Development cohort(n1 = 1918) | Validation cohort(n2 = 718) | p value | |
|---|---|---|---|---|
Age,mean(range) | 58.15(25–93) | 58.55(21–83) | 0.3896 | |
Sex | Female | 1017(53.02%) | 415(53.34%) | 0.915 |
Male | 901(46.98%) | 363(46.66%) | ||
Smoke | No | 1361(70.96%) | 573(73.65%) | 0.174 |
Yes | 557(29.04%) | 205(26.35%) | ||
Alcohol | No | 1623(84.62%) | 679(87.28%) | 0.088 |
Yes | 295(15.38%) | 99(12.72%) | ||
Family cancer history | No | 1496(78%) | 598(76.86%) | 0.555 |
Yes | 422(22%) | 180(23.14%) | ||
Individual cancer history | No | 1833(95.57%) | 732(94.09%) | 0.128 |
Yes | 85(4.43%) | 46(5.91%) | ||
Tumor size | 2.11(0.4-5) | 2.15(0.3-5) | 0.3970 | |
NTI | No | 1872(97.6%) | 750(96.4%) | 0.110 |
Yes | 46(2.4%) | 28(3.6%) | ||
PI | No | 1328(69.24%) | 542(69.67%) | 0.864 |
Yes | 590(30.76%) | 236(30.33%) | ||
LVI | No | 1675(87.33%) | 672(86.38%) | 0.544 |
Yes | 243(12.67%) | 106(13.62%) | ||
RUL | No | 1270(66.21%) | 516(66.32%) | 0.993 |
Yes | 648(33.79%) | 262(33.68%) | ||
RML | No | 1783(92.96%) | 717(92.16%) | 0.519 |
Yes | 135(7.04%) | 61(7.84%) | ||
RLL | No | 1558(81.23%) | 640(82.26%) | 0.568 |
Yes | 360(18.77%) | 138(17.74%) | ||
LUL | No | 1431(74.61%) | 568(73.01%) | 0.417 |
Yes | 487(25.39%) | 210(26.99%) | ||
LLL | No | 1630(84.98%) | 671(86.25%) | 0.436 |
Yes | 288(15.02%) | 107(13.75%) | ||
MD | No | 593(30.92%) | 257(33.03%) | 0.305 |
Yes | 1325(69.08%) | 521(66.97%) | ||
LD | No | 1424(74.24%) | 566(72.75%) | 0.453 |
Yes | 494(25.76%) | 212(27.25%) | ||
HD | No | 1819(94.84%) | 733(94.22%) | 0.578 |
Yes | 99(5.16%) | 45(5.78%) | ||
Acinus component | No | 377(19.66%) | 147(18.89%) | 0.6900 |
Yes | 1541(80.34%) | 631(81.11%) | ||
Mp component | No | 1591(82.95%) | 646(83.03%) | 1.0000 |
Yes | 327(17.05%) | 132(16.97%) | ||
Papillary component | No | 1319(68.77%) | 537(69.02%) | 0.934 |
Yes | 599(31.23%) | 241(30.98%) | ||
Solid component | No | 1664(86.76%) | 665(85.48%) | 0.414 |
Yes | 254(13.24%) | 113(14.52%) | ||
Lepidic component | No | 1543(80.45%) | 621(79.82%) | 0.751 |
Yes | 375(19.55%) | 157(20.18%) | ||
Mucous component | No | 1840(95.93%) | 741(95.24%) | 0.486 |
Yes | 78(4.07%) | 37(4.76%) | ||
Papillary predominant | No | 1618(84.36%) | 667(85.73%) | 0.401 |
Yes | 300(15.64%) | 111(14.27%) | ||
Solid predominant | No | 1792(93.43%) | 723(92.93%) | 0.700 |
Yes | 126(6.57%) | 55(7.07%) | ||
Lepidic predominant | No | 1747(91.08%) | 698(89.72%) | 0.301 |
Yes | 171(8.92%) | 80(10.28%) | ||
MP predominant | No | 1878(97.91%) | 762(97.94%) | 1.0000 |
Yes | 40(2.09%) | 16(2.06%) | ||
Mucous predominant | No | 1906(99.37%) | 767(98.59%) | 0.074 |
Yes | 12(0.63%) | 11(1.41%) | ||
Acinus predominant | No | 649(33.84%) | 273(35.09%) | 0.564 |
Yes | 1269(66.16%) | 505(64.91%) |